HIV/AIDS News & Information

Diagnosis

Diagnosis of B. anthracis can be made through a standard blood culture in six- to 24 hours. The lab must differentiate between other Bacillus species that may resemble B. anthracis, such as in the B. cereus group. One can differentiate based on morphological features; colonies of B. anthracis are nonhemolytic, are white to gray, and have been described as resembling ground glass. Polymyx-in-lysozyme-EDTA-thallous agar is used as a selective medium for B. anthracis. It is important to note that even after one- to two doses of cheap antibiotics, blood cultures may appear negative. Therefore, it is imperative that a sample be obtained before antibiotics are administered. Sputum culture is not a good indicator for the presence of inhalation anthrax, given the lack of a pneumonic process. A gram stain may be beneficial when looking for B. anthracis in vesicle fluid of cutaneous anthrax origin. Given the possibility that a person with a high index of suspicion may be negative on a gram stain or has already started canadian antibiotics, a punch biopsy is recommended, and the specimen should be sent for a definitive diagnosis. A laboratory response network (LRN) can make a definitive diagnosis. Here, confirmatory tests— such as immunohistochemical staining, gamma phage, and polymerase chain reaction (PCR)—may be performed. Antibodies to B. anthracis cell wall and capsule are used to perform immunohistochemical tests of pleural fluid or transbronchial biopsy specimens. Intact bacilli or B. anthracis antigens can be detected in this manner. Serologic tests have also proven to be valuable. An enzyme-linked immunosorbent assay (ELISA) is used to detect immunoglobulin (Ig) G response to B. anthracis protective antigen and capsular compo­nent. It may take as little as 10 days to detect antibody to the protective antigen, however, the greatest amount of IgG may not be detected until 40 days after onset of symptoms. Nasal swab analysis is also another method of detecting the presence of B. anthracis, however, it should only be used for epidemiological purposes. There are no data showing the use of nasal swabs as a prognostic tool. A positive nasal swab only indicates that there has been exposure to B. anthracis. Radiological tests have proven to be an excellent diagnostic tool such as chest X-ray or a chest CT scan. It is common on the chest X-ray and CT scan to find mediastinal widening, infiltrates/consolidation, air bron-chograms, necrotizing pneumonic lesions, and pleural effusions. In addition, on a CT scan, it is common to find hyperdense mediastinal and hilar adenopathy, lymphadenopathy, and mediastinal edema. It is important to note that some of these radiographic findings are not particular to B. anthracis. A differential diagnosis includes histoplasmosis, sarcoidosis, tuberculosis, and lymphoma. Postmortem findings and autopsy data have provided an abundance of clues as to the pathological effects of anthrax. Thoracic hemorrhagic necrotizing lymphadenitis and hemorrhagic necrotizing mediastinitis have been seen upon autopsy. Hemorrhagic meningitis and multiple gastrointestinal submucosal hemorrhagic lesions have been seen in several Sverdlovsk cases.

Differential Diagnosis

A differential diagnosis of inhalation versus influenza-like illness (ILI) is a challenge. A misdiagnosis may have resulted in improper discharge and eventual death of one anthrax victim. ILI is a nonspecific respiratory illness characterized by fever, fatigue, cough, sore throat, and rhinorrhea. Some of the viruses that cause ILI includes: rhi-novirus, respiratory syncytial virus (RSV), adenovirus, and parainfluenza virus. One clear distinction of inhalation anthrax is that it is not passed on from person to person, whereas ILI is communicable. Respiratory infections occur through the year, however, ILI caused by influenza and RSV peak during wintertime.
buy antibiotics in canada

Nasal congestion and rhinorrhea are features not associated with inhalation anthrax. Also, there are no unusual radiographic findings associated with influenza-associated pneumonia, unlike inhalation anthrax. It is suggested that blood cul tures should not be routinely obtained in patients with ILI symptoms unless there is suspected bacteremia and a high index of suspicion. Rapid identification tests are available for influenza and RSV, although lacking sensitivity, and should be performed within the first three- to four days of symptoms. Sensitivities to influenza in rapid tests are in the range of45-90%, which may result in a large proportion of the population having false negatives. Specificities are in the range of 60- 95%. It is recommended that rapid influenza tests be used with viral cultures in specific populations, such as nursing home residents and at clinics. There are no rapid screening tests available to diagnosis anthrax. The CDC recommends vaccination as a best measure of prevention against influenza, especially in those >65 years of age and six months to 64 years of age who have high-risk medical conditions. Other risk factors include those in the healthcare delivery. It is important to know that the vaccine can prevent 70-90% of the infections caused by influenza but does not prevent ILI caused by other viruses—most often the case.

Vaccination

There are several recommendations based on historical information, limited animal data, and in vitro data for treatment of anthrax. Current recommendations point to the use of the U.S. anthrax vaccine in conjunction with generic antibiotics. However, the use of this vaccine is still regarded as preventative.

The U.S. vaccine is also known as anthrax vaccine-adsorbed (AVA) consists of an aluminum hydroxide precipitate preparation of inactivated cell-free product made from cell-free filtrate of nonen-capsulated attenuated strain of B. anthracis. AVA is administered as a prophylactic measure subcuta-neously in 0.5 ml doses repeated at two- and four weeks and six-, 12-, and 18-month intervals, followed by boosters annually. However, since it was not licensed to be given for postexposure, it was given under investigational new drug procedures; three doses were administered at two-week intervals and as an adjunct to postexposure prophylaxis.

In studies conducted with nonhuman primates, it was found that postexposure vaccination was not found to be significantly effective unless a proper course of antibiotic therapy was administered in conjunction. The safety of the AVA has not definitively been established. There have been numerous military servicemen who had been given the vac­cine, and no apparent major side effect has been seen. The Institute of Medicine (IOM) has concluded that the AVA vaccine is safe and effective if given as an adjunct to antibiotic therapy. levitra uk

Therapy

There are no controlled clinical studies in humans with inhalation anthrax and the use of antibiotics. The Working Group at the Center for Civilian Biodefense, based at the Johns Hopkins School of Public Health and Medicine, has made several recommendations for the proper use of antibiotics based upon their expertise and the best available evidence. Historically, penicillin drug has been the drug of choice for anthrax; however, there are possible concerns of resistance. Low-level beta-lactamase has been observed in isolates. Genomic sequence data has shown two beta-lactames: 1) a penicillinase class (A) and 2) a cephalosporinase class (B). Resistance has been shown to sulfamethoxazole, trimethoprim, cefuroxime tablet, cefotaxime sodium, aztreonam, and ceftazidime. Penicillin exerts its antimicrobial activity by inhibiting bacterial cell wall synthesis. In the tetracyline class of drugs, doxycycline drug is preferred because it has been shown to be effective in nonhuman primate studies. Doxycycline exerts its antimicrobial activity by inhibiting bacterial protein synthesis. Ciprofloxacin generic belongs to the fluoroquinolone class of antimicrobials, which inhibit DNA-gyrase in susceptible organisms. Ciprofloxicin has been shown to be very effective in animal models and, therefore, the preferred of the class, although theoretically, other agents in the fluoroquinolone class may be as effective. It also has a better CNS penetration, compared to doxycycline tablet, but not as much as penicillin. CDC guidelines recommend the use of two or three antibiotics in combination based on susceptibility testing. Testing of 65 isolates at the CDC was performed along with isolates from the 2001 attack. Sensitivities were found with quinilones, rifampin, tetracycline, vancomycin, imipenem, meropenem, chloramphenicol, clindamycin, and aminoglycosides. It remains unclear whether or not the use of two or more antibiotics results in better survival outcomes. It has been reported that the strain of B. anthracis in the 2001 attacks was engineered to be resistant to the tetracyline and penicillin class of antibiotics drug. There are concerns that a newly engineered anthrax strain may originate in a future attack. Thus, the use of combination therapy is recommended. Clindamycin has been recommended based on its theoretical antitoxin production activity in streptococcal infections. The CDC also recommends the use of intravenous antimicrobial therapy; however, there can be certain limitations to this in the event that there is a massive anthrax attack. The Working Group recommends the use of either flouro-quinilones or doxycycline for the duration of 60 days. Amoxicillin drug is an appropriate alternative, if there are contraindications to the antibiotics mentioned above. Current postexposure prophylaxis, FDA-approved drugs include ciprofloxacin, generic doxycycline, and penicillin medication G procaine for inhalation anthrax. More research needs to be conducted into the long-term effects of these antibiotics. There were several concerns among those who were given ciprofloxacin in regards to side effects.